NSA2P2

Across TCGA pan-cancer cohorts, NSA2P2 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of NSA2P2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where NSA2P2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NSA2P2 is over-expressed in tumor, although a few such as BRCA and COAD show the opposite, repressed pattern.

LIHC, CHOL, and BRCA are the cancer types where NSA2P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NSA2P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	III,IV	+0.134	.015	3	view →
CHOL	All	All	+0.098	.004	2	view →
BRCA	Female	All	−0.046	.005	2	view →
COAD	Female	IV	−0.250	.006	1	view →
STAD	Male	IV	−0.164	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

NSA2P2–LIHC

Open the LIHC breakdown →